We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genincode Plc | LSE:GENI | London | Ordinary Share | GB00BL97B504 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.15 | 0.00 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 3.80 | 4.50 | 4.15 | 4.15 | 4.15 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 2.16M | -7.02M | -0.0396 | -1.05 | 7.34M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 4.15 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/9/2024 | 17:02 | ALNC |  EARNINGS: Origin Enterprises profit falls; GENinCode loss narrows |
| 25/9/2024 | 06:00 | UK RNS | GENinCode PLC Half-year Report |
| 20/9/2024 | 10:01 | ALNC | GENinCode partners with medical centres for cardiovascular screening |
| 20/9/2024 | 06:36 | UK RNS | GENinCode PLC Collaboration with The Family Heart Foundation |
| 09/9/2024 | 06:00 | UK RNS | GENinCode PLC Notice of Results |
| 28/8/2024 | 06:00 | UK RNS | GENinCode PLC CARDIO inCode-Score presentation |
| 27/6/2024 | 15:02 | UK RNS | GENinCode PLC Result of AGM |
| 05/6/2024 | 16:17 | UK RNS | GENinCode PLC Posting of Annual Report and Notice of AGM |
| 03/6/2024 | 13:14 | ALNC | GENinCode revenue grows amid continued international expansion |
| 03/6/2024 | 06:00 | UK RNS | GENinCode PLC Final Results |
Genincode (GENI) Share Charts1 Year Genincode Chart |
|
1 Month Genincode Chart |
Intraday Genincode Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 12/11/2024 08:20 by Genincode Daily Update Genincode Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GENI. The last closing price for Genincode was 4.15p.Genincode currently has 176,960,000 shares in issue. The market capitalisation of Genincode is £7,343,840. Genincode has a price to earnings ratio (PE ratio) of -1.05. This morning GENI shares opened at 4.15p |
Posted at 05/6/2024 16:47 by g2theary Bough back 50k as I took profits on the Monday ... will carry on buying here now I like this price ... |
Posted at 10/5/2024 16:38 by albert35911 How wonderful to miss a party like geni.15p. Bwaaah lolol |
Posted at 18/1/2024 13:45 by timbo003 Yes, Investors are currently in a mind set that persuades them the next fund raise will inevitably be at lower price than the last one, irrespective of progress made by the company in question. This will revert back to the more normal paradigm (eventually) whereby successive fund raisings are conducted at higher prices to reflect positive progress, but alas, I cannot see that happening in the short term. |
Posted at 18/1/2024 09:55 by timbo003 I picked up a few GENI shares in the placing, it was EIS qualifying, so the up front tax relief means an effective purchase price of 3.5p/share for UK tax payers (like myself)The blurb which came round with the placing documentation stated they were looking to raise £5m in the firm placing, plus anything extra in the retail offer. The initial indicative price was 5p/share and that didn't shift throughout the 5 day period between when I was made inside and when they announced the placing. |
Posted at 18/1/2024 09:12 by jimtech In September Interims Presentation (link below) management said they will need to raise £8m.The December fundraise was for only £4m. Consequently, whilst any good news may temporarily spike the share price, the knowledge that another £4m is needed will - in my view - temper it. hxxps://youtu.be/pLN |
Posted at 07/12/2023 18:26 by jimtech I'm positive and have recently bought in but it's going to take some time.Have only taken a half position as fundraise larger than their current MCap (£5m) is required. They will likely hope FDA kit approval and resulting RNS will boost share price so they can raise. This, of course, assumes approval. Patience required. And maybe more funds. |
Posted at 14/10/2023 10:45 by sharesoc ShareSoc is holding its first hybrid event in London on 19th Oct. Hear from GENincode (GENI) and other healthcare companies like Tristel Plc (TSTL), Inspiration Healthcare Group (IHC), Creo Medical Group (CREO) and Abingdon Health (ABDX). Attend in-person or online.📍 |
Posted at 30/8/2023 06:18 by toffeeman Nice RNS this morning - but will it impact the share price? |
Posted at 15/12/2021 14:57 by hedgehog 100 At just 33.5p the GENI share price is getting a bit silly now.The IPO on 22nd. July was at 44p, and that looked a bargain. Since when there has been steady progress. I'm a big fan of 'overhang plays', because when the supply of cheap shares dries up, the share price can rebound quite dramatically, which is what I fully expect to happen here. |
Posted at 31/10/2021 12:09 by hedgehog 100 22/07/2021 07:00 UK Regulatory (RNS & others) GENinCode PLC Admission to trading on AIM & First Day of Dealing LSE:GENI Genincode Plc"... On 28 April 2021, the Company announced a partnership to provide genetic testing from labs based at Royal Brompton and Harefield Hospitals. Following this, it was announced on 14 June 2021 that a product commercialisation agreement had been entered into with EVERSANA in the US. The Directors believe that the partnership with EVERSANA, a leading provider of global commercial services to the life science industry, will provide a significant opportunity for the Group to progress its commercialisation plans for the US. ..." "GENinCode announces major US commercialisation partnership with EVERSANA Posted on June 14, 2021 Oxford, UK. — 14, June 2021 — GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces its partnership with EVERSANA Life Sciences LLC (“EVERSANA&rdq EVERSANA is a leading provider of global commercial services to the life sciences industry. In the United States, GENinCode will utilise EVERSANA’s COMPLETE Commercialisation model fully integrating services that include market access, agency services, clinical and commercial field teams, medical science liaisons, channel management, health economics and outcomes research and compliance, with each service optimised by data and predictive analytics. The suite of expertise will underpin and accelerate the launch of GENinCode’s first product Cardio inCode for the risk assessment of CVD in primary prevention. The EVERSANA group comprises over 4,000 employees. GENinCode specialises in polygenic risk assessment for the onset of cardiovascular disease with the Company’s technology providing clinicians with genetic risk assessment and AI bioinformatics to inform, predict and prevent cardiovascular events. CVD is the leading cause of death and disability worldwide accounting for one in every four deaths in the United States. In 2010, the global cost of CVD was approximately US $863 billion. By 2030, this figure is set to rise to US $1,044 billion and is both a major health issue and global economic burden. CVD is a broad disease classification which encompasses conditions such as coronary artery disease (causing angina, heart attacks, heart failure), cerebrovascular disease (causing stroke, and some dementia), peripheral vascular disease (causing limb ischaemia, and some chronic kidney disease) and venous thromboembolism. GENinCode will deliver its portfolio of polygenic CVD products through its partnership with EVERSANA. GENinCode and EVERSANA have a vision to inform patients about their cardiovascular risk and to improve public health by using the predictive capability of genomics to assist in making lifestyle choices and targeting treatment to improve patient outcomes. Over the past 15 years GENinCode has amassed significant investment in its research, data, bioinformatics technology and product development to assess disease risk to prevent the onset of CVD. Matthew Walls, CEO, GENinCode said: “We have worked closely with the EVERSANA team over the past 12 months and are delighted to announce our US partnership. EVERSANA provide proven launch and commercialisation expertise to support our market access and will help accelerate our speed to market.” Jim Lang, CEO of EVERSANA said: “GEN inCode’s approach to understanding and addressing genetic risk is revolutionary and as such, these products demand a commercialisation model that bypasses traditionally strategies to acceleration launch, access and impact. EVERSANA is eager to put the full power of our platform to work.” For more information visit www.genincode.com Enquiries: GENinCode UK Limited Tamsin Jeffs Tel +44 (0)7800 903435 EVERSANA Sarah Zwicky Tel +1 (414) 434-4691 About GENinCode GENinCode is a UK based company specializing in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide. GENinCode UK Limited operates business units in Europe and Latin America through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. GENinCode’s predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. To learn more about GENinCode, visit www.genincode.com or connect through LinkedIn and Twitter. About EVERSANA EVERSANA™ is the leading provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life science solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
